Keywords
Conventional treatment
Lymphoma
Submitted : 2022-06-27
Accepted : 2022-07-12
Published : 2022-07-27
Abstract
Objective: To analyze the clinical effect of pegaspargase combined with chemotherapy on patients with lymphoma. Methods: Seventy patients with lymphoma admitted to Shaanxi Provincial People’s Hospital between December 2020 and June 2021 were selected as study subjects and were equally divided into the control group and the intervention group using the lottery method, with 35 cases in each group; the control group received conventional treatment, while the intervention group received pegaspargase combined with chemotherapy. The treatment satisfaction, quality of life, psychological status, and incidence of adverse reactions of the patients in the two groups were compared. Results: The differences in the indicators between the two groups were statistically significant (p < 0.05). Conclusion: Pegaspargase combined with chemotherapy can effectively improve the treatment effect and satisfaction of lymphoma patients; hence, it is worthy of promotion in clinical treatment.
References
Liu CC, Zhang JY, Xiong CL, et al., 2020, Effect of Pemesterase on Coagulation Function and Relapse Rate in Patients with Lymphoma. Laboratory Medicine and Clinics, 17(14): 2075–2077.
Zu L, Zhou J, Zhang GL, et al., 2020, Three Cases of Relapsed/Refractory T-Cell Lymphoma/Leukemia Treated with Decitabine in Combination with Chemotherapy and Review of the Literature. Journal of Clinical Hematology,33(3): 211–214.
Lu B, 2021, Effectiveness of Dasatinib Combined with Pemantase Chemotherapy Regimen in the Treatment of Patients with Ph-Positive Acute Lymphoblastic Leukemia. Chinese and Foreign Medical Research, 19(25): 138–140.
Yang J, Yan H, Chai L, et al., 2020, Effect of SMILE Regimen on Coagulation Function in Patients with NK/T-Cell Lymphoma. China Drugs and Clinics, 20(23): 3931–3933.
Hu L, Xia M, Li GQ, et al., 2020, Clinical Observation of P-GEMOX Regimen for the First-Line Treatment of Primary Extranasal NK/T-Cell Lymphoma. Leukemia & Lymphoma, 29(3): 160–164.
Chen X, Chen X, Xu G, 2020, Nursing Experience of Sindilizumab Combined with Pemantase, Anrotinib in the Treatment of Primary NK/T-Cell Lymphoma. Chinese and Western Medicine Nursing, 6(10): 285–287.
Han X, 2021, Evaluation of Pemesterase Combined with GEMOX Chemotherapy Regimen in the Treatment of NK/T-Cell Lymphoma. Contemporary Medicine Series, 19(17): 69–71.
Xia C, 2020, Impact of Remission Status After Induction Chemotherapy for Early-Stage Nasal NK/T-Cell Lymphoma on Survival with Combination Therapy. South China University.
Wang S, Pan X, Qi Y, 2020, Meta-Analysis of Pepmonidase and Levomucoidase in the Treatment of Acute Lymphoblastic Leukemia in Chinese Children. Journal of Shenyang Medical College, 22(3): 251–255.
Zhang J, 2021, Analysis of the Effect of Pemesterase Injection on the Chemotherapeutic Effect of NKT Lymphoma. Clinical Research, 29(3): 78–79.
Zhang Z, 2021, Efficacy and Safety Analysis of Pemantase in the Treatment of Extranodal NK/T-Cell Lymphoma. Chinese Community Physicians, 37(24): 59–60.
Sun Y, Lou ZS, 2020, Meta-Analysis of Pemesterase in the Treatment of Extranodal NK/T-Cell Lymphoma. Journal of Mudanjiang Medical College, 41(3): 59–65.
Wang J, Huang G, Cui K, 2020, Effect of Pemesterase on Lipid Levels in Patients with Extranasal NK/T-Cell Lymphoma. Shaanxi Medical Journal, 49(4): 481–484.
Wei Q, Zhang Y, Wang W, et al., 2021, Clinical Characteristics of Patients with Single-Center Extranodal NK/T-Cell Lymphoma and Prognosis Analysis Based on Pemesterase Chemotherapy. Chinese Journal of Experimental Hematology, 29(3): 735–740.
Zhang G, Liu Y, Zhang Y, 2013, The Effect of Pegaspargase on Coagulation Function in Patients with Lymphoma. China Journal of New Drugs, 22(19): 2281–2285.
Lai WP, Zheng RH, Qin PF, et al., 2021, Efficacy of Cetapenem Combined with Chemotherapy in the Treatment of Peripheral T-Cell Lymphoma. China Practical Medicine, 16(19): 25–27.
Liang S, Wen F, 2020, New Advances in the Treatment of Acute Lymphoblastic Leukemia in Children with Silent Inactivation of Pemesterase. International Journal of Blood Transfusion and Hematology, 43(5): 418–422.
Zhou R, Liu W, 2021, Safety Analysis and Management Measures of Pemesterase in the Treatment of Lymphatic System Tumors. China Prescription Drugs, 19(8): 90–91.
Liu YB, Yuan XL, Ma RJ, et al., 2021, Efficacy and Safety of Programmed Death Receptor 1 Inhibitor in Combination with Chemotherapy for Primary Stage III/IV Extranodal NK/T-Cell Lymphoma. Chinese Medical Journal, 101(16): 1178–1181.
He Y, Zhang L, Yu X, et al., 2020, Effectiveness of PEG-ASP Combined with CHOP Regimen Chemotherapy and Sequential Radiotherapy in the Treatment of Stage I-II Nasal NK/T-Cell Lymphoma. The Great Physician, 5(1): 23–25.